NASDAQ : ALLO
Allogene Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 407.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Allogene Therapeutics, Inc. (ALLO) reported revenue of 4.64M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 4.64M | 22.00K | 95.00K | 156.00K | 114.09M | |
| Cost of Revenue | 122.52M | 150.15M | 192.30M | 242.91M | 256.39M | 220.18M |
| Gross Profit | -117.88M | -150.15M | -192.28M | -242.82M | -256.23M | -106.09M |
| Selling, General & Admin | 62.44M | 56.78M | 65.20M | 71.67M | 79.31M | 74.11M |
| Operating Expenses | 62.44M | 56.78M | 65.20M | 71.67M | 79.31M | 74.11M |
| Operating Income | -180.32M | -206.93M | -257.48M | -314.49M | -335.54M | -180.19M |
| Interest Expense | -1.30M | -1.07M | -181.00K | |||
| Interest & Investment Income | 15.81M | 19.29M | 20.15M | 18.31M | 4.57M | 1.71M |
| Earnings From Equity Investments | -1.69M | -10.67M | -12.88M | -4.09M | ||
| Other Non Operating Income (Expenses) | 317.00K | 215.00K | -275.00K | -163.00K | 3.44M | 517.00K |
| EBT Excluding Unusual Items | -165.49M | -188.50M | -239.47M | -307.02M | -340.41M | -182.05M |
| Gain (Loss) on Sale of Investments | -1.96M | -7.00M | ||||
| Asset Writedown | -2.38M | -15.72M | -13.24M | |||
| Pretax Income | -165.49M | -190.89M | -257.15M | -327.26M | -340.41M | -182.05M |
| Income Tax Expense | 443.00K | |||||
| Net Income | -165.49M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
| Net Income to Common | -165.49M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
| Shares Outstanding (Basic) | 254.47M | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M |
| Shares Outstanding (Diluted) | 254.47M | 220.62M | 194.81M | 156.93M | 143.15M | 135.82M |
| EPS (Basic) | -0.65 | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| EPS (Diluted) | -0.65 | -0.87 | -1.32 | -2.09 | -2.38 | -1.34 |
| Free Cash Flow | -102.60M | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Free Cash Flow Per Share | -0.40 | -0.68 | -1.03 | -1.52 | -1.58 | -1.52 |
| Gross Margin | -92.99% | |||||
| Operating Margin | -3,886.14% | -1,170,372.73% | -331,044.21% | -215,087.18% | -157.94% | |
| Profit Margin | -3,566.68% | -1,170,863.64% | -344,489.47% | -218,214.10% | -159.57% | |
| Free Cash Flow Margin | -2,211.16% | -913,609.09% | -251,841.05% | -144,685.90% | -180.79% | |
| EBITDA | -168.65M | -194.57M | -243.84M | -300.29M | -321.24M | -169.74M |
| EBITDA Margin | -148.78% | |||||
| D&A For EBITDA | 11.67M | 12.36M | 13.64M | 14.20M | 14.29M | 10.45M |
| EBIT | -180.32M | -206.93M | -257.48M | -314.49M | -335.54M | -180.19M |
| EBIT Margin | -157.94% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 38.63M | 51.69M | 75.22M | 83.16M | 61.90M | 173.31M |
| Short-Term Investments | 293.98M | 198.52M | 217.26M | 365.54M | 455.42M | 283.99M |
| Cash & Short-Term Investments | 332.60M | 250.21M | 292.48M | 448.70M | 517.32M | 457.30M |
| Other Receivables | 2.20M | 1.50M | 1.90M | 1.70M | 3.30M | 6.00M |
| Receivables | 2.20M | 1.50M | 1.90M | 1.70M | 3.30M | 6.00M |
| Prepaid Expenses | 5.20M | 6.04M | 9.01M | 8.72M | 8.20M | 8.02M |
| Total Current Assets | 340.00M | 257.75M | 303.39M | 459.12M | 528.82M | 471.32M |
| Property, Plant & Equipment | 105.12M | 112.73M | 131.26M | 163.18M | 196.43M | 181.02M |
| Long-Term Investments | 90.99M | 8.04M | 80.67M | 3.65M | 79.47M | 370.18M |
| Other Long-Term Assets | 13.98M | 37.39M | 33.39M | 16.90M | 16.86M | 16.11M |
| Total Assets | 550.09M | 415.90M | 548.71M | 642.84M | 821.58M | 1.04B |
| Accounts Payable | 5.96M | 4.27M | 5.39M | 5.90M | 13.89M | 10.26M |
| Accrued Expenses | 17.11M | 17.64M | 21.55M | 21.98M | 29.73M | 29.65M |
| Current Portion of Leases | 8.66M | 8.21M | 7.51M | 6.78M | 6.00M | 3.20M |
| Current Unearned Revenue | 86.00K | 95.00K | 423.00K | |||
| Other Current Liabilities | 2.40M | 1.07M | 2.34M | 4.02M | 4.65M | |
| Total Current Liabilities | 31.73M | 32.51M | 35.52M | 37.08M | 53.73M | 48.17M |
| Long-Term Leases | 70.35M | 75.05M | 83.25M | 88.35M | 95.12M | 69.93M |
| Other Long-Term Liabilities | 11.84M | 15.80M | 7.76M | 5.18M | 5.85M | 4.12M |
| Total Liabilities | 113.92M | 123.36M | 126.53M | 130.60M | 154.70M | 122.23M |
| Common Stock | 345.00K | 229.00K | 212.00K | 169.00K | 144.00K | 142.00K |
| Additional Paid-In Capital | 2.53B | 2.30B | 2.24B | 2.08B | 1.91B | 1.82B |
| Retained Earnings | -2.10B | -2.01B | -1.82B | -1.56B | -1.23B | -903.35M |
| Comprehensive Income & Other | -518.00K | 269.00K | -89.00K | -955.00K | -9.93M | -2.57M |
| Shareholders' Equity | 436.18M | 292.54M | 422.18M | 512.23M | 666.88M | 916.41M |
| Total Liabilities & Equity | 550.09M | 415.90M | 548.71M | 642.84M | 821.58M | 1.04B |
| Total Debt | 79.01M | 83.25M | 90.76M | 95.12M | 101.12M | 73.13M |
| Net Cash (Debt) | 253.59M | 166.96M | 201.72M | 353.58M | 416.20M | 384.17M |
| Net Cash Per Share | 1.00 | 0.76 | 1.04 | 2.25 | 2.91 | 2.83 |
| Filing Date Shares Outstanding | 345.49M | 243.78M | 217.26M | 169.09M | 144.50M | 142.75M |
| Total Common Shares Outstanding | 345.35M | 229.41M | 212.21M | 168.64M | 144.44M | 142.62M |
| Working Capital | 308.27M | 225.24M | 267.86M | 422.04M | 475.10M | 423.15M |
| Book Value Per Share | 1.26 | 1.28 | 1.99 | 3.04 | 4.62 | 6.43 |
| Tangible Book Value | 436.18M | 292.54M | 422.18M | 512.23M | 666.88M | 916.41M |
| Tangible Book Value Per Share | 1.26 | 1.28 | 1.99 | 3.04 | 4.62 | 6.43 |
| Machinery | 37.83M | 37.84M | 40.47M | 41.94M | 41.15M | 37.96M |
| Construction In Progress | 28.00K | 39.00K | ||||
| Leasehold Improvements | 107.54M | 107.54M | 108.13M | 108.62M | 108.55M | 108.35M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -165.49M | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
| Depreciation & Amortization | 11.67M | 12.36M | 13.64M | 14.20M | 14.29M | 10.45M |
| Asset Writedown & Restructuring Costs | 2.38M | 15.72M | 13.24M | |||
| Loss (Gain) From Sale of Investments | -3.94M | -4.22M | -6.39M | 191.00K | 2.89M | 6.96M |
| Loss (Gain) on Equity Investments | 1.69M | 10.67M | 12.88M | 4.09M | ||
| Stock-Based Compensation | 37.49M | 37.64M | 51.74M | 65.95M | 83.60M | 80.82M |
| Other Operating Activities | -413.00K | 4.36M | 5.69M | 6.58M | 2.33M | -73.13M |
| Change in Accounts Payable | 1.22M | -1.23M | -503.00K | -7.50M | 4.87M | -767.00K |
| Change in Unearned Revenue | -21.00K | -38.30M | ||||
| Change in Other Net Operating Assets | 17.27M | -9.65M | -24.30M | -13.80M | -950.00K | 7.12M |
| Operating Cash Flow | -102.20M | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Capital Expenditures | -402.00K | -386.00K | -694.00K | -1.52M | -5.19M | -21.45M |
| Investment in Securities | -131.20M | 95.94M | 76.38M | 164.81M | 111.35M | 185.10M |
| Investing Cash Flow | -131.60M | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Issuance of Common Stock | 220.09M | 23.25M | 114.39M | 95.69M | 2.95M | 11.96M |
| Other Financing Activities | 6.91M | 2.28M | ||||
| Financing Cash Flow | 220.09M | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
| Net Cash Flow | -13.71M | -23.53M | -7.94M | 21.25M | -111.41M | -9.19M |
| Free Cash Flow | -102.60M | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Free Cash Flow Margin | -2,211.16% | -913,609.09% | -251,841.05% | -144,685.90% | -180.79% | |
| Free Cash Flow Per Share | -0.40 | -0.68 | -1.03 | -1.52 | -1.58 | -1.52 |
| Levered Free Cash Flow | -63.46M | -80.73M | -99.13M | -134.26M | -111.74M | -85.97M |
| Unlevered Free Cash Flow | -62.65M | -80.06M | -99.02M | -134.26M | -111.74M | -85.97M |
| Change in Working Capital | 18.49M | -10.88M | -24.80M | -21.31M | 3.90M | -31.95M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 407.68M | 307.88M | 446.60M | 540.17M | 907.08M | 2.13B |
| Enterprise Value | 154.08M | 140.83M | 247.56M | 171.34M | 457.39M | 1.70B |
| Last Close Price | 1.18 | 1.37 | 2.13 | 3.21 | 6.29 | 14.92 |
| PS Ratio | 87.86 | 20,300.07 | 5,685.98 | 5,814.63 | 18.64 | |
| PB Ratio | 0.93 | 1.05 | 1.06 | 1.05 | 1.36 | 2.32 |
| P/TBV Ratio | 0.93 | 1.05 | 1.06 | 1.05 | 1.36 | 2.32 |
| EV/Sales Ratio | 33.21 | 11,252.80 | 1,803.61 | 2,931.99 | 14.87 | |
| Debt / Equity Ratio | 0.18 | 0.28 | 0.21 | 0.19 | 0.15 | 0.08 |
| Net Debt / Equity Ratio | -0.58 | -0.57 | -0.48 | -0.69 | -0.62 | -0.42 |
| Net Debt / EBITDA Ratio | 1.50 | 0.86 | 0.83 | 1.18 | 1.30 | 2.26 |
| Net Debt / FCF Ratio | 2.47 | 1.12 | 1.00 | 1.48 | 1.84 | 1.86 |
| Asset Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.10 | |
| Quick Ratio | 10.55 | 7.74 | 8.29 | 12.15 | 9.69 | 9.62 |
| Current Ratio | 10.72 | 7.93 | 8.54 | 12.38 | 9.84 | 9.78 |
| Return on Equity (ROE) | -42.39% | -53.42% | -55.13% | -55.51% | -43.00% | -18.24% |
| Return on Assets (ROA) | -22.08% | -26.82% | -27.01% | -26.84% | -22.55% | -9.94% |
| Return on Capital Employed (ROCE) | -34.80% | -54.00% | -50.20% | -51.90% | -43.70% | -18.20% |
| Earnings Yield | -55.11% | -62.00% | -57.68% | -60.59% | -37.53% | -8.56% |
| FCF Yield | -25.17% | -48.60% | -45.01% | -44.29% | -24.88% | -9.70% |
| Buyback Yield / Dilution | -19.13% | -13.25% | -24.14% | -9.63% | -5.39% | -12.84% |